{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAK-385&page=2", "query": { "intervention": "TAK-385", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAK-385&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T20:01:31.095Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03085095", "title": "A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1134, "start_date": "2017-04-18", "completion_date": "2021-11-26", "has_results": true, "last_update_posted_date": "2022-01-18", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 27, "location_summary": "Tucson, Arizona • Orange, California • Denver, Colorado + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Pompano Beach", "state": "Florida" }, { "city": "Jeffersonville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03085095" }, { "nct_id": "NCT06922318", "title": "The COSMYC Trial (COmbined Suppression of MYC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "ZEN-3694", "type": "DRUG" }, { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) analogue", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2025-08-19", "completion_date": "2031-08-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06922318" }, { "nct_id": "NCT06130995", "title": "Relugolix + Enzalutamide Study in High-Risk Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Androgen Deprivation Therapy", "Locally Advanced Prostate Cancer" ], "interventions": [ { "name": "Relugolix and Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 46, "start_date": "2024-12-26", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT06130995" }, { "nct_id": "NCT04513717", "title": "Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Adenocarcinoma", "Stage III Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Buserelin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Histrelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Magnetic Resonance Elastography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Relugolix", "type": "DRUG" }, { "name": "Triptorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2753, "start_date": "2021-01-21", "completion_date": "2038-12-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 594, "location_summary": "Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04513717" }, { "nct_id": "NCT05679388", "title": "A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Prostate Cancer Metastatic", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Relugolix Pill", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2023-02-13", "completion_date": "2024-08-05", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05679388" }, { "nct_id": "NCT03049735", "title": "LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 388, "start_date": "2017-04-26", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 76, "location_summary": "Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049735" }, { "nct_id": "NCT05739123", "title": "Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pregnancy Related", "Pregnancy Complications", "Pregnancy, High Risk" ], "interventions": [ { "name": "Relugolix-Containing Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma Switzerland GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": null, "sex": "FEMALE", "summary": "0 Years and older · Female only" }, "enrollment_count": 728, "start_date": "2023-05-08", "completion_date": "2033-05", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 1, "location_summary": "Wilmington, North Carolina", "locations": [ { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05739123" }, { "nct_id": "NCT03654274", "title": "SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "FEMALE", "summary": "18 Years to 51 Years · Female only" }, "enrollment_count": 802, "start_date": "2018-05-22", "completion_date": "2023-01-31", "has_results": true, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 60, "location_summary": "Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654274" }, { "nct_id": "NCT03103087", "title": "LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 382, "start_date": "2017-06-14", "completion_date": "2020-09-16", "has_results": true, "last_update_posted_date": "2022-04-20", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03103087" }, { "nct_id": "NCT07142551", "title": "Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) analogue", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2026-03-09", "completion_date": "2034-06-01", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-09-25T20:01:31.095Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07142551" } ] }